Close

Ratings by Jefferies (Dennis Ding)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
9/27/2023 Roivant Sciences ROIV Maintain Buy
(N/A)
 
 
  Details
6/27/2023 Cara Therapeutics CARA Maintain Buy
(N/A)
 
 
  Details
6/20/2023 Milestone Pharmaceuticals MIST Downgrade Hold
(Buy)
3.74
(1.70)
-54.55% Details
6/7/2023 Veru, Inc. VERU Upgrade Hold
(Underperform)
1.06
(0.59)
-44.34% Details
5/30/2023 Cara Therapeutics CARA New Coverage Buy
(N/A)
3.28
(0.91)
-72.26% Details
5/30/2023 Lyra Therapeutics LYRA New Coverage Buy
(N/A)
2.43
(5.30)
118.11% Details
5/30/2023 Ardelyx, Inc ARDX New Coverage Buy
(N/A)
3.29
(8.68)
163.83% Details
4/3/2023 Pardes Biosciences PRDS Downgrade Hold
(N/A)
1.32
(2.16)
63.64% Details
2/24/2023 Esperion Therapeutics ESPR New Coverage Buy
(N/A)
5.83
(2.61)
-55.23% Details
2/15/2023 Corcept Therapeutics CORT Downgrade Hold
(Buy)
23.06
(22.45)
-2.65% Details
12/19/2022 NewAmsterdam Pharma Co NV NAMS New Coverage Buy
(Buy)
12.00
(23.14)
92.83% Details
10/17/2022 NGM Biopharmaceuticals NGM Downgrade Hold
(Buy)
11.55
(1.91)
-83.46% Details
8/8/2022 Cincor Pharma Inc CINC Maintain Buy
(N/A)
 
 
  Details
7/27/2022 Corcept Therapeutics CORT New Coverage Buy
(N/A)
26.81
(22.45)
-16.26% Details
7/20/2022 NGM Biopharmaceuticals NGM New Coverage Buy
(N/A)
15.01
(1.91)
-87.28% Details
2/2/2022 Arbutus Biopharma ABUS Upgrade Buy
(Hold)
2.81
(2.92)
3.91% Details
2/1/2022 Cincor Pharma Inc CINC New Coverage Buy
(N/A)
18.11
(29.06)
60.46% Details
1/18/2022 Pardes Biosciences PRDS New Coverage Buy
(N/A)
13.95
(2.16)
-84.52% Details
12/29/2021 Arbutus Biopharma ABUS New Coverage Hold
(N/A)
3.86
(2.92)
-24.35% Details
11/30/2021 Sigilon Therapeutics SGTX Downgrade Hold
(Buy)
3.77
(22.47)
496.02% Details
10/26/2021 Roivant Sciences ROIV New Coverage Buy
(N/A)
7.04
(11.60)
64.77% Details